- Stocks
- Healthcare
- NASDAQ: BCDA

Price (delayed)

$3.43

Market cap

$56.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$35.25M

Sector: Healthcare

Industry: Biotechnology

BCDA's quick ratio has soared by 167% from the previous quarter

BCDA's gross margin has soared by 96% YoY and by 12% from the previous quarter

BioCardia's net income has increased by 3.3% from the previous quarter but it has decreased by 2% YoY

BioCardia's revenue has plunged by 80% YoY and by 54% from the previous quarter

BioCardia's gross profit has plunged by 60% YoY and by 48% from the previous quarter

What are the main financial stats of BCDA

Market
Valuations
Earnings

Shares outstanding

16.34M

Market cap

$56.04M

Enterprise value

$35.25M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.22

Price to sales (P/S)

239.36

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

243.1

Revenue

$145,000

EBIT

-$15M

EBITDA

-$14.44M

Free cash flow

-$12.39M

Per share
Balance sheet
Liquidity

EPS

-$1.48

Free cash flow per share

-$1.22

Book value per share

$1.54

Revenue per share

$0.01

TBVPS

$2.31

Total assets

$23.42M

Total liabilities

$4.25M

Debt

$614,000

Equity

$19.18M

Working capital

$18.41M

Debt to equity

0.03

Current ratio

5.33

Quick ratio

5.24

Net debt/EBITDA

1.44

Margins
Efficiency
Dividend

EBITDA margin

-9,955.2%

Gross margin

97.2%

Net margin

-10,347.6%

Operating margin

-10,709.7%

Return on assets

-119%

Return on equity

-204.9%

Return on invested capital

N/A

Return on capital employed

-78.2%

Return on sales

-10,345.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the BioCardia stock price performed over time

Intraday

3.31%

1 week

-0.58%

1 month

-16.14%

1 year

-16.14%

YTD

-0.87%

QTD

-20.97%

How have BioCardia's revenue and profit performed over time

Revenue

$145,000

Gross profit

$141,000

Operating income

-$15.53M

Net income

-$15M

Gross margin

97.2%

Net margin

-10,347.6%

BioCardia's operating margin has shrunk by 116% QoQ

The net margin has dropped by 109% since the previous quarter

BCDA's gross margin has soared by 96% YoY and by 12% from the previous quarter

BioCardia's revenue has plunged by 80% YoY and by 54% from the previous quarter

What is BioCardia's growth rate over time

What is BioCardia stock price valuation

P/E

N/A

P/B

2.22

P/S

239.36

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

243.1

The EPS has grown by 43% YoY and by 23% from the previous quarter

BCDA's P/B is 84% below its 5-year quarterly average of 13.2

BCDA's P/S is 123% above its last 4 quarters average of 103.8 and 52% above its 5-year quarterly average of 152.5

BioCardia's revenue has plunged by 80% YoY and by 54% from the previous quarter

How efficient is BioCardia business performance

The ROS has plunged by 109% from the previous quarter

The company's return on equity has surged by 79% YoY and by 59% QoQ

The ROA has grown by 47% YoY and by 33% from the previous quarter

What is BCDA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BCDA.

How did BioCardia financials performed over time

BCDA's current ratio has soared by 168% QoQ

BCDA's quick ratio has soared by 167% from the previous quarter

The debt is 97% smaller than the equity

BioCardia's debt to equity has plunged by 94% YoY and by 90% from the previous quarter

The debt has dropped by 51% since the previous quarter and by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.